Bioxytran Inc (QB) (BIXT) Quote

$BIXT Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z

RIGHTEOUS!! Thanks LOADS, Eco-M!

$BIXT Emerging Markets live about 1PM EST CEO and VP interview today

https://emerginggrowth.com/emerging-growth-conference-73/

GM Sir. and YES there is!!! $BIXT has gone for panhandling for 1 Million dollars, to scoring a 3 entity JV 10-30 Million dollar funding, NO DILUTION deal for one of other inventions they have

PR is out folks. This should rally hard the rest of this week. $BIXT
10-30 Million dollar non dilutive, JV, staged funding is done.
12 Bagger upside to 2023 High.

Also the S-1 cash raise filing was withdrawn, and cancelled.

BIXT does not need money now.

https://www.globenewswire.com/en/news-release/2024/07/18/2915310/0/en/Bioxytran-Launches-Joint-Venture-with-the-Heme-Foundation-for-Development-of-Universal-Oxygen-Carrier.html

Crazy good news. Fingers crossed this pumps to a $1

News tomorrow clarifying. $$$

Read my last post above.

10-30 Million dollar JV, non dilutive, solved the problem. It's all good, in fact it is awesome news. All of it.

Yes, an 8-K days ago, and an 8-K today, PR coming tomorrow and online live Emerging markets interview tomorrow.

$NDPD $BIXT Heme News

BIXT JV 8-K is out this morning
JV means Joint Venture!!!!!
Ding Ding Ding Ding
https://www.otcmarkets.com/filing/html?id=17684798&guid=IDO-kePo6PoFJth
"Item 1.01 Entry into a Material Definitive Agreement

On July 15, 2024, Bioxytran (the “Company”) entered into a Joint Venture Agreement (“JV Agreement”) with the Heme Foundation1 (“Heme”), and NDPD Pharma, Inc.2 (“NDPD”).

The JV Agreement outlines each partners contribution and right in the development of the Universal Oxygen Carrier (“UOC”).

Bioxytran’s Universal Oxygen Carrier represents a potential paradigm shift in transfusion medicine and life-saving blood oxygenation therapy. The inception of UOC began with a profound understanding of the physiological mechanisms governing oxygen delivery. Insights into carbohydrate science have led to the creation of this revolutionary product, making UOC essentially invisible to the human immune system. As a result, UOC circumvents the issue of immune rejection commonly found with other blood substitutes.

UOC is a hemoglobin-based oxygen carrier (“HBOC”) designed to mimic the oxygen transportation function of red blood cells. The first HBOC was discovered in the mid-1930’s. While HBOC’s show promise as a blood alternative, there are side-effects associated with HBOC’s, such as high blood pressure, and the risk of organ damage. Unlike other HBOC’s, treatment with UOC has shown no known side-effects in any studies."

BIXT JV News is with two entities, 10-30 Million dollars funding for the BIXT Oxygen carrier that is designed to avoid brain damage .....

Read the 8-K for the whole story.

Also the S-1 shelf offering was withdrawn earlier this week, because BIXT does not need money now. This is massive back to $ land news.

Yes, an 8-K days ago, and an 8-K today, PR coming tomorrow and online live Emerging markets interview tomorrow.

$NDPD $BIXT Heme News

BIXT JV 8-K is out this morning
JV means Joint Venture!!!!!
Ding Ding Ding Ding
https://www.otcmarkets.com/filing/html?id=17684798&guid=IDO-kePo6PoFJth
"Item 1.01 Entry into a Material Definitive Agreement

On July 15, 2024, Bioxytran (the “Company”) entered into a Joint Venture Agreement (“JV Agreement”) with the Heme Foundation1 (“Heme”), and NDPD Pharma, Inc.2 (“NDPD”).

The JV Agreement outlines each partners contribution and right in the development of the Universal Oxygen Carrier (“UOC”).

Bioxytran’s Universal Oxygen Carrier represents a potential paradigm shift in transfusion medicine and life-saving blood oxygenation therapy. The inception of UOC began with a profound understanding of the physiological mechanisms governing oxygen delivery. Insights into carbohydrate science have led to the creation of this revolutionary product, making UOC essentially invisible to the human immune system. As a result, UOC circumvents the issue of immune rejection commonly found with other blood substitutes.

UOC is a hemoglobin-based oxygen carrier (“HBOC”) designed to mimic the oxygen transportation function of red blood cells. The first HBOC was discovered in the mid-1930’s. While HBOC’s show promise as a blood alternative, there are side-effects associated with HBOC’s, such as high blood pressure, and the risk of organ damage. Unlike other HBOC’s, treatment with UOC has shown no known side-effects in any studies."

BIXT JV News is with two entities, 10-30 Million dollars funding for the BIXT Oxygen carrier that is designed to avoid brain damage .....

Read the 8-K for the whole story.

Also the S-1 shelf offering was withdrawn earlier this week, because BIXT does not need money now. This is massive back to $ land news.

We lose our money for now?

That post was from almost one year ago...Is there any article more recent that would clue us in on Bioxytran's current progress? Thanks!

https://bioxytraninc.us4.list-manage.com/track/click?u=3ab1704628c56ed50088fc32b&id=5f88f5d23a&e=6b153bfc39

Macchio is correct. From MDX website (notice the vague answers--tricky wording on several items on website??)

Q. WHAT IS THE REGULATORY STATUS OF THE DEVELOPED MEDICAL DEVICE?

A. MDX Life Sciences is capable to provide a FDA approved device that will monitor 4 physiological
parameters from tissues of patients in real time. The TMS will need a special approval by the FDA.

Where do you do your DD dude? The library of the Roman Empire or the Middle ages?|

More Hogwash and fairy tails just like you did on IFUS, before you got schooled and educated by me?

https://www.slideserve.com/cana/avraham-mayevsky

"MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. The device measures the consumption of oxygen molecules in tissues on a cellular level.

The output of the MDX Viewer is the Brain Metabolic Score BMS, which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (AOC) molecule called BXT-25. Bioxytran plans on using the BXT-25 in its clinical trials for ischemic stroke and Alzheimer’s disease patients as a way to replace hyperbaric oxygen treatment (HBOT).

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

The device is already FDA Approved:

"The book is directly tied to the Hypoxia platform technology which uses the MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. "

You said: He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.

I read that she won a Nobel prize already
Are you talking about Avraham Mayevsky? The advisor is a "he" not a "she" and "he" didn't win a Nobel prize. He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.

BTW, David Platt (CEO of BIXT) and Ola Soderquist (CFO of BIXT) are also managers in MDX Life Sciences. You can find info on the company at MDX Life Sciences. The MDX Viewer is being used to validate BXT-25 and neither of these products have FDA approval. I'm not sure how useful the MDX Viewer and associated TMS score are and also am not clear on the relationship between BIXT and MDX Life Sciences. The MDX Viewer and BXT-25 seem to be tightly linked - they might both be revolutionary products or could both end up in the ashbin of history. I hope it is the former.

Nice rally today up 9.65% on slow pre Holiday day

I noticed a 1/2 Million share bid show up this week and the well known naked shorts/MMs backed up in a panic looking for cloths and fresh shelter. It was rather comical.

Reminded me of

You still panhandle bashing for the paychecks at the Hedge fund/Broker dealer, trying to manipulate the stock price for chump change?

Do not forget, I read that she won a Nobel Prize already

$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

The CEO has been running around for years telling the same BS story. Ask him how last company did?

If there’s any chance on earth that this medical technology can do anything on that scale even close isn’t it a gift from heaven?

Nobody noticed.

This is very promising and exciting for the company and shareholders

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

do you not have anything better to do then try and bad mouth ecomike all over ihub.
I have made more money thanks to ecomike then from anyone else.

So much potential and so little progress. They have been talking about performing a dosing study for over a year now and still don't seem to have started. And the dosing study is required before they can even begin Phase III testing. What the heck is going on? They set up their Indian subsidiary at the end of 2022 for commercialization and they still seem to be sitting on their hands, waiting for what?

The latest news is painting a bleak picture for the future of COVID... experts predict that, with repeated COVID infections, everyone will eventually be suffering from long COVID. BIXT has a solution but doesn't seem to feel any urgency.

Sounds like a dud. PPS remains depressed

**BIXT Live chat starts in 15 minutes**

MIAMI , June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.
The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Register for the Conference here.
https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=globe
Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com

**BIXT is at 1:10 PM today (I think EST zone since the conference firm is in Florida?)**

What would you like to know about BIXT?

Just read an article about this : anybody have any real
Insight about the actual company ?

Just read an article about this : anybody have any real
Insight about the actual company ?

100% go look at RVVTF which he pumped incessantly as it tanked

If EGOmike is pumping you better be dumping.

No one has pumped on more no bid stocks than the Ego.

Please read and share this

https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158

Yes I believe you are correct

Share this good news with everyone you know!

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax

The first description of avian influenza (AI) dates back to 1878 in northern Italy, when Perroncito [Perroncito E. Epizoozia tifoide nei gallinacei. Annali Accad Agri Torino 1878;21:87-126] described a contagious disease of poultry associated with high mortality.

The vaccine wasn't created for the bird flu...The bird flu was created for the vaccine. So let's keep everyone sick. After all, from Merck's point of view, heal a patient\lose a customer...The disease management system we're saddled with has made the United States' pharmaceutical labyrinth the laughing stock of the civilized world during the past forty years. Pity...

The vaccine wasn't created for the bird flu; the bird flu was created for the vaccine....Heal a patient, lose a customer...I think that pretty much explains what's wrong with the disease management system that's made the U.S. the laughing stock of the civilized world during the past 40 years...

BIXT CTB Cost To Borrow is already over 78% annual interest rate, up over 30000% above normal.

Shorts on BIXT got played..

Folks you have a choice. Bill Gate's Death by clot shot, if the Bird Flu vaccine or enhanced, Added gain of function, new improved bird flu, Bird flu a la Bill Gates research lab leaks the newer more dangerous bird flu they created for vaccine research....

Or BIXT, who has a published patent covering/targeting the galectin fold of 60+ viruses including bird flu and RSV, HIV, Epstein Barr's trigger MS, and Covid(all strains) and long haul covid19 with a non toxic oral pill, that has zero side effects?

Hard choice I know...

Is Big Pharma afraid of losing trillions of dollars of sales when BIXT gets approved and succeeds? 100% paranoid yes. So much so they have shorted the hell out of BIXT...

This is us, verses Big Pharama and their investors now

They will loose...

https://childrenshealthdefense.org/defender/united-states-bankrolling-creation-deadlier-contagious-bird-flu-strains/?utm_source=luminate&utm_medium=email&utm_campaign=defender&utm_id=20240520

YES!!!!

Dumb Money's (The Movie) Game Stop savior ROARING-KITTY that Bankrupted Ken Griffins 6.8 billions dollar hedge fund in 2021 is back today, after an 18 month break.
That stock and Amc rallied biggly today, So maybe we recuit them to get eyes on BIXT?

I agree that the National Institutes of Health and\or the US Military would be very useful collaborators in any attempt to establish a viable market for BIXT's biotech...But would either of them be willing to take a flier on a bulletin board company with no revenues? I certainly hope so, but...

Why not work with NIH?

It is indeed an ethical (and a preemptive) project that should be undertaken by anyone interested in avoiding the pain and extraordinary expense of current medical treatments typically prescribed for the very conditions Bioxytran appears equipped to address...That expressed, I'm nervous that Bioxytran may remain on the sidelines indefinitely unless the right kind (and number) of private (and retail) investors come forward to invest.

As always, we'll see...
C

That is why I call BIXT an ethical Investment in our health, that we the people need to fight for.